Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Anthracycline analogs The past, present, and future

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Acton EM, Tong GL, Mosher CW et al. (1984) Intensely potent morpholinyl anthracyclines. J Med Chem 27 638–645

  2. 2.

    Armand JP (1984) Phase II and phase III studies with equirubicin in breast cancer in France. In Bonadonna G (ed) Advances in anthracycline chemotherapy epirubicin. Masson, Milan, pp 75–82

  3. 3.

    Arcamone E (1980) The development of new antitumor anthracyclines. Med Chem 16: 1–41

  4. 4.

    Arcamone F, Cassinelli G, Orezzi P et al. (1964) Daunomycin II. The structure and stereochemistry of daunosamine. J Am Chem Soc 86: 5335–5336

  5. 5.

    Arcamone F, Penco S, Vigevani A et al (1975) Synthesis and antitumor properties of new glycosides of daunomycinone and adriamycinone. J Med Chem 18: 703–707

  6. 6.

    Arcamone F, Penco S, Vigevani A (1975) Adriamycin (NSC-123127) new chemical developments and analogs. Cancer Chemother Rep (3): 6: 123–129

  7. 7.

    Arcamone F, Penco S, Redaelli S et al. (1976) Synthesis and antitumor activity of 4′-deoxydaunorubicin and 4′-deoxyadriamycin. J Med Chem 19: 1424–1425

  8. 8.

    Arcamone F, Bernardi L, Giardino P et al. (1976) Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-diepidaunorubicin, and their β anomers. Cancer Treat Rep 60: 829–834

  9. 9.

    Berman E, Wittes RE, Leyland-Jones B et al. (1983) Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer. Cancer Res 43: 6096–6101

  10. 10.

    Berman E, Casper ES, Howard J et al. (1984) Phase II trial of 4′-epi-doxorubicin in patients with advanced malignant melanoma. Cancer Treat Rep 68: 679–680

  11. 11.

    Bhuyan BK, McGovren JP, Crampton SL (1981) Intracellular uptake of 7-con-O-methylnogarol and adriamycin by cells in culture and its relationship to cell survival. Cancer Res 41: 882–887

  12. 12.

    Blum RH, Garnick MB, Israel M (1979) Initial clinical evaluation of N-trifluoroacetyladriamycin 14-valerate (AD-32), an adriamycin analog. Cancer Treat Rep 63: 919–923

  13. 13.

    Bonadonna G, Monfardini S, de Lena M et al. (1969) Clinical evaluation of adriamycin, a new antitumour antibiotic. Br Med J 3: 503–506

  14. 14.

    Bonadonna G, Brambilla, Rossi A, et al. (1984) Epirubicin in advanced breast cancer. The experience of the Milan Cancer Institute. In Bonadonna G (ed) Advances in anthracycline chemotherapy epirubicin. Masson, Milan, pp 63–70

  15. 15.

    Bonfante V, Bonadonna G, Villani F et al. (1979) Preliminary phase I study of 4′-epi-adriamycin. Cancer Treat Rep 63: 915–918

  16. 16.

    Bonfante V, Villani F, Bonadonna G (1982) Toxic and therapeutic activity of 4′-epi-doxorubicin. Tumori 68: 105–111

  17. 17.

    Bonfante V, Ferrari L, Villani F et al. (1983) Phase I study of 4-demethoxydaunorubicin. Invest New Drugs 1 161–168

  18. 18.

    Bonfante V, Rossi A, Brambilla C et al. (1985) Comparative activity and toxicity of adriamycin (ADM) and new anthracycline analogs in advanced breast cancer (abstract). Proc Am Assoc Cancer Res 26: 165

  19. 19.

    Broggini M, Colombo T, Martini A et al. (1980) Studies on the comparative distribution and biliary excretion of doxorubicin and 4′-epi-doxorubicin in mice and rats. Cancer Treat Rep 64: 897–904

  20. 20.

    Broggini M, Italia C, Colombo T et al. (1984) Activity and distribution of iv and oral 4-demethoxydaunorubicin in murine experimental tumors. Cancer Treat Rep 68 739–747

  21. 21.

    Brown TD, Donehower RC, Grochow LB et al. (1985) A phase I study of menogaril (MEN) in patients with advanced cancer (abstract). Proc Am Soc Clin Oncol 4: 32

  22. 22.

    Bull JM, Tormey DC, Li S-H et al. (1978) A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer 41: 1649–1657

  23. 23.

    Campora E, Nobile MT, Sertoli MR et al. (1984) Phase II study of 4′-epi-doxorubicin in advanced breast cancer. Cancer Treat Rep 68: 1285–1286

  24. 24.

    Carella AM, Santini G, Martinengo M et al. (1985) 4-demethoxydaunorubicin (idarubicin) in refractory or relapsed acute leukemias. A pilot study. Cancer 55: 1452–1454

  25. 25.

    Carella AM, Santini G, Giordano D et al. (1985) Idarubicin alone or in combination with citarabine and etoposide (3+3+5 protocol) in acute non-lymphoblastic leukaemia. Leukemia Res 9: 631

  26. 26.

    Casazza AM (1979) Experimental evaluation of anthracycline analogs. Cancer Treat Rep 63: 835–844

  27. 27.

    Casazza AM, Guiliani FC (1984) Preclinical properties of epirubicin. In Bonadonna G (ed) Advances in anthracycline chemotherapy epirubicin. Masson, Milan, pp 31–40

  28. 28.

    Casazza AM, Di Marco A, Bertazzoli C et al. (1978) Antitumor activity, toxicity, and pharmacological properties of 4′-epi-adriamycin. In Siegenthaler A, L▵hy R (eds) Current chemotherapy, vol 2. American Society of Microbiology, Washington, pp 1257–1260

  29. 29.

    Casazza AM, Di Marco A, Bonadonna G et al. (1980) Effects of modifications in position 4 of the chromophore or in position 4′ of the aminosugar, on the antitumor activity and toxicity of daunorubicin and doxorubicin. In Crooke ST, Reich SD (eds) Anthracyclines current status and new developments. Academic, New York, pp 403–430

  30. 30.

    Casazza AM, Pratesi G, Giuliani et al. (1980) Antileukemia activity of 4-demethoxydaunorubicin in mice. Tumori 66 549–564

  31. 31.

    Casazza AM, Savi G, Pratesi G et al. (1983) Antitumor activity in mice of 4′-deoxydoxorubicin in comparison with doxorubicin. Eur J Cancer Clin Oncol 19: 411–418

  32. 32.

    Casazza AM, Barbieri B, Fumagalli A et al. (1981) Biologic activity of 4-demethoxy-13-dihydrodaunorubicin (4-dm-13-OH-DNR) (abstract). Proc Am Assoc Cancer Res 24 251

  33. 33.

    Daghestani AN, Arlin ZA, Leyland-Jones B et al. (1985) Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia. Cancer Res 45: 1408–1412

  34. 34.

    Dickinson AC, DeJordy JO, Boutin MG et al. (1984) Absence of generation of oxygen-containing free radicals with 4′-deoxydoxorubicin, a non-cardiotoxic anthracycline drug. Biochem Biophys Res Commun 125: 584–591

  35. 35.

    Di Marco A, Gaetani M, Dorigotti L et al. (1963) Studi sperimentali sull ‘attivita’ antineoplastica del nuovo antibiotico daunomicina. Tumori 49: 203–217

  36. 36.

    Di Marco A, Gaetani M, Scarpinato B (1969) Adriamycin (NSC-123,127) a new antibiotic with antitumor activity. Cancer Chemother Rep (1) 53: 33–37

  37. 37.

    Di Marco A, Casazza AM, Pratesi G (1977) Antitumor activity of 4-demethoxydaunorubicin administered orally. Cancer Treat Rep 62: 893–894

  38. 38.

    Di Marco A, Zunino F, Casazza AM (1978) Comparison of biochemical and biological methods in the evaluation of new anthracycline drugs. Antibiotics Chemother 23: 12–20

  39. 39.

    Dodion P, Davis TA, Rozencweig M et al. (1985) Human pharmacokinetics of esorubicin (4′-deoxydoxorubicin). Invest New Drugs 3: 361–368

  40. 40.

    Dodion P, Sessa C, Gerard N et al. (1985) Phase I trial of menogaril (M) with a single dose schedule (abstract). Proc Am Soc Clin Oncol 4: 26

  41. 41.

    Dorr FA, Von Hoff DD, Kuhn JG et al. (in press) Phase I clinical investigation of 7-con-O-methylnogaril, a new anthracycline antibiotic. Invest New Drugs

  42. 42.

    Dubost M, Ganter P, Maral R et al. (1964) Rubidomycin a new antibiotic with cytostatic properties. Cancer Chemother Rep 41: 35–36

  43. 43.

    Egorin MJ, Van Echo DA, Whitacre MY et al. (1986) Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (NSC 269148, 7-OMEN) and their correlation with clinical toxicities. Cancer Res 46: 1513–1520

  44. 44.

    Einzig A, Kelsen D, Cheng E et al. (1984) Phase II study of 4-demethoxydaunorubicin in patients with adenocarcinoma of the upper gastrointestinal tract. Cancer Treat Rep 68 1415–1416

  45. 45.

    Ferrari L, Rossi A, Brambilla C et al. (1984) Phase I study with 4′-deoxydoxorubicin. Invest New Drugs 2: 287–295

  46. 46.

    Formelli F, Pollini C, Casazza AM et al. (1981) Fluorescence assays and pharmacokinetic studies of 4′-deoxydoxorubicin and doxorubicin in organs of mice bearing solid tumors. Cancer Chemother Pharmacol 5: 139–144

  47. 47.

    Fossa SD, Wik B, Bae E, et al. (1982) Phase II study of 4′-epi-doxorubicin in metastatic renal cancer. Cancer Treat Rep 66: 1219–1221

  48. 48.

    Ganzina F (1983) 4′-epi-doxorubicin, a new analogue of doxorubicin a preliminary overview of preclinical and clinical data. Cancer Treat Rev 10: 1–22

  49. 49.

    Garewal HS, Robertone A, Salmon SE et al. (1984) Phase I trial of esorubicin (4′-deoxydoxorubicin). J Clin Oncol 2 1034–1039

  50. 50.

    Gause GF, Brazhnikova MG, Shorin VA (1974) A new antitumor antibiotic, carminomycin (NSC-180024). Cancer Chemother Rep (1) 58: 255–256

  51. 51.

    Ghione M (1975) Development of adriamycin (NSC-123127). Cancer Chemother Rep (3) 6: 83–89

  52. 52.

    Giuliani FC, Kaplan NO (1980) New doxorubicin analogs active against doxorubicin-resistant colon tumor xenografts in the nude mouse. Cancer Res 40: 4682–4687

  53. 53.

    Giuliani FC, Zirvi KA, Kaplan NO et al. (1981) Chemotherapy of human colorectal tumor xenografts in athymic mice with clinically active drugs 5-fluorouracil and 1-3-Bis-(2-chloroethyl)-1-nitrosourea (BCNU). Comparison with doxorubicin derivatives 4′-deoxydoxorubicin and 4′-O-methyldoxorubicin. Int J Cancer 27: 5–13

  54. 54.

    Goldin A, Venditti JM, Geran R (1985) The effectiveness of the anthracycline analog 4′-epidoxorubicin in the treatment of experimental tumors a review. Invest New Drugs 3 3–21

  55. 55.

    Hakes TB, Daghestani AN, Dougherty JB et al. (1985) Phase II study of 4-demethoxydaunorubicin in advanced ovarian carcinoma. Cancer Treat Rep 69: 559–560

  56. 56.

    Harper HD, Kemeny NE, Ahmed T et al. (1984) Phase II trial of 4-demethoxydaunorubicin in advanced colorectal carcinoma. Cancer Treat Rep 618: 689–690

  57. 57.

    Hayat M, Hurteloup P, Parmentier C et al. (1984) Phase I trial of idarubicin (4-demethoxydaunorubicin) in adult acute leukemia. Invest New Drugs 2: 375–379

  58. 58.

    Hochster HS, Green MD, Speyer J et al. (1985) 4′-epidoxorubicin (epirubicin) activity in hepatocellular carcinoma. J Clin Oncol 3: 1535–1540

  59. 59.

    Holdener EE, Hansen HH, Høst H et al. (1985) Epirubicin in colorectal cancer. A phase II study of the early clinical trials group (EORTC). Invest New Drugs 3: 63–66

  60. 60.

    Holdener EE, Cavalli F, Hansen HH et al. (1985) Phase II trial of esorubicin in advanced colorectal cancer (abstract). Proc Am Soc Clin Oncol 4: 93

  61. 61.

    Hortobagyi G, Yap HY, Aboud A et al. (1984) Doxorubicin (D) vs 4′-epidoxorubicin (4ED) for metastatic breast cancer (MBC) a prospective randomized study (abstract). Proc Am Soc Clin Oncol 3: 121

  62. 62.

    Hurteloup P, Cappelaere P, Armand JP et al. (1983) Phase II clinical evaluation of 4′-epi-doxorubicin. Cancer Treat Rep 67: 337–341

  63. 63.

    Jain KK, Casper ES, Geller NL et al. (1985) A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 3 818–826

  64. 64.

    Jensen RA, Acton EM, Peters JH (1984) Electrocardiographic and transmembrane potential effects of 5-iminodaunorubicin in the rat. Cancer Res 44: 4030–4039

  65. 65.

    Joss RA, Hansen HH, Hansen M et al. (1984) Phase II trial of epirubicin in advanced squamous, adeno- and large cell carcinoma of the lung. Eur J Cancer Clin Oncol 20 495–499

  66. 66.

    Joss RA, Obrecht J-P, Alberto P et al. (1984) Phase II trial of 4-demethoxydaunorubicin in patients with non-small cell lung cancer. Cancer Treat Rep 68: 563–564

  67. 67.

    Kaplan S, Sessa C, Willems Y et al. (1984) Phase I trial of 4-demethoxydaunorubicin (idarubicin) with single oral doses. Invest New Drugs 2: 281–286

  68. 68.

    Kaplan S, Sessa C, Joss R et al. (1985) Phase II trial of 4′-deoxydoxorubicin in advanced non-small cell lung cancer. Cancer Treat Rep 69: 1337–1338

  69. 69.

    Kris MG, Gralla RJ, Kelsen DP et al. (1985) Phase II trial of oral 4-demethoxydaunorubicin in patients with non-small cell lung cancer. Am J Clin Oncol (CCT) 8: 377–379

  70. 70.

    Lambertenghi-Deliliers G, Maiolo AT, Annaloro C et al. (1984) Complete remission in prolymphocytic leukemia with 4-demethoxydaunorubicin and arabinosyl cytosine. Cancer 54: 199–201

  71. 71.

    Leitner SP, Casper ES, Hakes TB et al. (1985) Phase II trial of 4′-deoxydoxorubicin in patients with advanced breast cancer. Cancer Treat Rep 69: 1319–1320

  72. 72.

    Lopez M, Perno C-F, Papaldo P et al. (1984) Phase II study of epirubicin in advanced malignant melanoma. Invest New Drugs 2: 315–317

  73. 73.

    Lopez M, Di Lauro L, Ganzina F et al. (1985) Epirubicin in non-Hodgkin's lymphomas. Am J Clin Oncol (CCT) 8 151–153

  74. 74.

    Macrez C, Marneffe-Lebrequier H, Ripault J et al. (1967) Accidents cardiaques observés au cours des traitements par la rubidomycine. Pathol-Biol 15: 949–953

  75. 75.

    Martoni A, Pacciarini MA, Pannuti F et al. (1985) Activity of 4-demethoxydaunorubicin by the oral route in advanced breast cancer. Eur J Cancer Clin Oncol 21: 803–806

  76. 76.

    Mathé G, Umezawa H, Tapiero H et al. (1985) Oriented phase II trial in advanced breast cancer of 4′-o-tetrahydropyranyl-adriamycin (THP-ADM), a non hair, non heart toxic anthracycline (abstract). Proc Am Soc Clin Oncol 4 71

  77. 77.

    McGovren JP (1980) Activity of the anthracycline agent, 7-con-O-methylnogarol (7-OMEN) administered orally to mice bearing P388 or L1210 leukemia. Cancer Treat Rep 64: 727–729

  78. 78.

    McGovren JP, Neil GL, Denlinger RH et al. (1979) Chronic cardiotoxicity studies in rabbits with 7-con-O-methylnogarol, a new anthracycline antitumor agent. Cancer Res 39 4849–4855

  79. 79.

    McGovren JP, Nelson KG, Lassus M et al. (1984) Menogaril a new anthracycline agent entering clinical trials. Invest New Drugs 2: 359–367

  80. 80.

    Meyers FJ, Lewis B, Mitchell E et al. (1985) Phase II trial of 4′-epi-doxorubicin in advanced colorectal carcinoma a Northern California Oncology Group study. Cancer Treat Rep 69: 143–144

  81. 81.

    Michaelson R, Kemeny N, Young C (1982) Phase II evaluation of 4′-epi-doxorubicin in patients with advanced colorectal carcinoma. Cancer Treat Rep 66: 1757–1758

  82. 82.

    Monti E, Piccinini F, Favalli L, et al. (1983) Role of the fast-exchanging calcium compartment in the early cardiotoxicity of anthracycline analogs. Biochem Pharmacol 32 3303–3306

  83. 83.

    Morin MJ, Sartorelli AC (1984) Inhibition of glycoprotein biosynthesis by the inducers of HL-60 cell differentiation, aclacinomycin A and marcellomycin. Cancer Res 44 2807–2812

  84. 84.

    Mouridsen HT, Somers R, Santoro A et al. (1984) Doxorubicin vs. epirubicin in advanced soft tissue sarcomas. An EORTC randomized phase II study. In Bonadonna G (ed) Advances in arthracycline chemotherapy epirubicin. Masson, Milan, pp 95–103

  85. 85.

    Nicaise C, Rozencweig M, DeMarneffe M et al. (1983) Clinical phase I trial with marcellomycin with a single-dose schedule. Eur J Cancer Clin Oncol 19: 449–454

  86. 86.

    Penco S, Casazza AM, Franchi G et al. (1983) Synthesis, antitumor activity, and cardiac toxicity of new 4-demethoxyanthracyclines. Cancer Treat Rep 67: 665–673

  87. 87.

    Pratesi G, Deschner EE (1984) The antitumoral activity of 4′-deoxydoxorubicin compared to doxorubicin and 5-fluorouracil in methylazoxymethanol acetate-induced colon tumors in CF1 mice. Cancer 54: 18–24

  88. 88.

    Ringenberg S, Propert K, Perry M et al. (1986) Deoxydoxorubicin (DxDx) in extensive non-small cell lung cancer (NSCLC) (abstract). Proc Am Soc Clin Oncol 5: 174

  89. 89.

    Ripault J, Weil M, Jacquillat C (1967) Etude nécropsique de quatre malades traités par la rubidomycine. Pathol-Biol 15: 955–957

  90. 90.

    Robert J, Vrignaud P, Nguyen-Ngoc T et al. (1985) Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer. Cancer Treat Rep 69: 633–640

  91. 91.

    Rozencweig M, Crespeigne N, Kenis Y (1983) Phase I trial with 4′-deoxydoxorubicin (esorubicin). Invest New Drugs 1: 309–313

  92. 92.

    Rozencweig M, ten Bokkel Huinink W, Cavalli F et al. (1984) Randomized phase II trial of carminomycin versus 4′-epidoxorubicin in advanced breast cancer. J Clin Oncol 2: 275–281

  93. 93.

    Scarffe JH, Kenny JB, Johnson RJ et al. (1985) Phase II trial of epirubicin in gastric cancer. Cancer Treat Rep 69 1275–1277

  94. 94.

    Schauer PK, Wittes RE, Gralla RJ (1981) A phase I trial of 4′-epi-Adriamycin. Cancer Clin Trials 4: 433–437

  95. 95.

    Scher HI, Yagoda A, Ahmed T et al. (1985) Phase-II trial of 4-demethoxydaunorubicin (DMDR) for advanced hypernephroma. Cancer Chemother Pharmacol 14: 79–80

  96. 96.

    Sessa C, Bosia L, Kaplan S et al. (1984) Phase I study of 4′-deoxydoxorubicin given weekly. Invest New Drugs 2 369–374

  97. 97.

    Sigman LM, Van Echo DA, Egorin MJ et al. (1985) Menogaril (7-OMEN, NSC 269148) phase I study (abstract). Proc Am Assoc Cancer Res 26: 170

  98. 98.

    Stanton GF, Raymond V, Wittes RE et al. (1985) Phase I and clinical pharmacological evaluation of 4′-deoxydoxorubicin in patients with advanced cancer. Cancer Res 45 1862–1868

  99. 99.

    Stanton G, Casper ES, Friedman B (1985) Phase II trial of 4-demethoxydaunorubicin in patients with advanced malignant melanoma. Cancer Treat Rep 69: 915–916

  100. 100.

    Supino R, Necco A, Dasdia T et al. (1977) Relationship between effects on nucleic acid synthesis in cell cultures and cytotoxicity of 4-demethoxy derivatives of daunorubicin and adriamycin. Cancer Res 37: 4523–4528

  101. 101.

    Tan C, Etcubanas E, Wollner N et al. (1973) Adriamycin —an antitumor antibiotic in the treatment of neoplastic diseases. Cancer 32: 9–17

  102. 102.

    Torti FM, Porzig KJ, Gandara DR et al. (1984) Phase II trial of 4′-epi-doxorubicin in metastatic melanoma. Cancer Treat Rep 68: 1509–1510

  103. 103.

    Weenen H, Lankelma J, Penders PGM et al. (1983) Pharmacokinetics of 4′epi-doxorubicin in man. Invest New Drugs 1: 59–64

  104. 104.

    Weenen H, Van Maanen JMS, De Planque MM et al. (1984) Metabolism of 4′-modified analogs of doxorubicin. Unique glucuronidation pathway for 4′-epidoxorubicin. Eur J Cancer Clin Oncol 20: 919–926

  105. 105.

    Weiss RB, Bruno S (1981) Daunorubicin treatment of adult solid tumors. Cancer Treat Rep 65 [Suppl 4]: 25–28

  106. 106.

    Wils JA (1984) Phase II trial of 4′-epi-doxorubicin in metastatic colorectal carcinoma. Invest New Drugs 2: 397–399

  107. 107.

    Wils J, Bleiberg H, Blijham G et al. (1985) Phase II study of epirubicin in advanced adenocarcinoma of the pancreas. Eur J Cancer Clin Oncol 21: 191–194

  108. 108.

    Wiley PF, Johnson JL, Houser DJ (1977) Nogalamycin analogs having improved antitumor activity. J Antibiot 30 628–629

Download references

Author information

Correspondence to Raymond B. Weiss.

Additional information

The opinions expressed in this article are solely those of the authors and are not necessarily those of any government agency

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Weiss, R.B., Sarosy, G., Clagett-Carr, K. et al. Anthracycline analogs The past, present, and future. Cancer Chemother. Pharmacol. 18, 185–197 (1986). https://doi.org/10.1007/BF00273384

Download citation

Keywords

  • Cancer Research
  • Anthracycline
  • Anthracycline Analog